A carregar...
Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas
BACKGROUND: Recurrent high-grade gliomas in adults remain a deadly cancer with median survival of less than 1 year. In the absence of effective agents, immunotherapy with checkpoint inhibitors has been adopted as a potentially beneficial next step for recurrences with hypermutated or mismatch repair...
Na minha lista:
| Publicado no: | Neurooncol Pract |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899050/ https://ncbi.nlm.nih.gov/pubmed/31832212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz016 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|